KR20130043611A - 레보플록사신 또는 그의 염 또는 그들의 용매화물을 함유하는 안감염증 치료용 점안제, 안감염증의 치료 방법, 레보플록사신 또는 그의 염 또는 그들의 용매화물, 및 그의 용도 - Google Patents

레보플록사신 또는 그의 염 또는 그들의 용매화물을 함유하는 안감염증 치료용 점안제, 안감염증의 치료 방법, 레보플록사신 또는 그의 염 또는 그들의 용매화물, 및 그의 용도 Download PDF

Info

Publication number
KR20130043611A
KR20130043611A KR1020127024069A KR20127024069A KR20130043611A KR 20130043611 A KR20130043611 A KR 20130043611A KR 1020127024069 A KR1020127024069 A KR 1020127024069A KR 20127024069 A KR20127024069 A KR 20127024069A KR 20130043611 A KR20130043611 A KR 20130043611A
Authority
KR
South Korea
Prior art keywords
levofloxacin
eye
infection
conjunctivitis
drop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127024069A
Other languages
English (en)
Korean (ko)
Inventor
다카시 나가노
고지 사카나카
마사츠구 나카무라
고우이치 가와즈
하지메 이부키
가요코 사카모토
Original Assignee
다이이찌 산쿄 가부시키가이샤
산텐 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이이찌 산쿄 가부시키가이샤, 산텐 세이야꾸 가부시키가이샤 filed Critical 다이이찌 산쿄 가부시키가이샤
Publication of KR20130043611A publication Critical patent/KR20130043611A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020127024069A 2010-02-25 2010-12-16 레보플록사신 또는 그의 염 또는 그들의 용매화물을 함유하는 안감염증 치료용 점안제, 안감염증의 치료 방법, 레보플록사신 또는 그의 염 또는 그들의 용매화물, 및 그의 용도 Ceased KR20130043611A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2010-040281 2010-02-25
JP2010040281 2010-02-25
PCT/JP2010/072685 WO2011104981A1 (ja) 2010-02-25 2010-12-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤、眼感染症の治療方法、レボフロキサシンもしくはその塩またはそれらの溶媒和物、ならびにその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177015979A Division KR20170070265A (ko) 2010-02-25 2010-12-16 레보플록사신 또는 그의 염 또는 그들의 용매화물을 함유하는 안감염증 치료용 점안제, 안감염증의 치료 방법, 레보플록사신 또는 그의 염 또는 그들의 용매화물, 및 그의 용도

Publications (1)

Publication Number Publication Date
KR20130043611A true KR20130043611A (ko) 2013-04-30

Family

ID=44506417

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127024069A Ceased KR20130043611A (ko) 2010-02-25 2010-12-16 레보플록사신 또는 그의 염 또는 그들의 용매화물을 함유하는 안감염증 치료용 점안제, 안감염증의 치료 방법, 레보플록사신 또는 그의 염 또는 그들의 용매화물, 및 그의 용도
KR1020177015979A Ceased KR20170070265A (ko) 2010-02-25 2010-12-16 레보플록사신 또는 그의 염 또는 그들의 용매화물을 함유하는 안감염증 치료용 점안제, 안감염증의 치료 방법, 레보플록사신 또는 그의 염 또는 그들의 용매화물, 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177015979A Ceased KR20170070265A (ko) 2010-02-25 2010-12-16 레보플록사신 또는 그의 염 또는 그들의 용매화물을 함유하는 안감염증 치료용 점안제, 안감염증의 치료 방법, 레보플록사신 또는 그의 염 또는 그들의 용매화물, 및 그의 용도

Country Status (16)

Country Link
US (1) US20120316158A1 (enExample)
EP (1) EP2540299B1 (enExample)
JP (3) JP5600056B2 (enExample)
KR (2) KR20130043611A (enExample)
CN (1) CN102770141A (enExample)
BR (1) BR112012021247A2 (enExample)
CA (1) CA2791190C (enExample)
EA (1) EA201290827A1 (enExample)
ES (1) ES2568647T3 (enExample)
MX (1) MX349603B (enExample)
MY (1) MY183483A (enExample)
NZ (1) NZ602126A (enExample)
PH (2) PH12012501674A1 (enExample)
SG (1) SG183427A1 (enExample)
TW (1) TWI488627B (enExample)
WO (1) WO2011104981A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2791190C (en) * 2010-02-25 2017-12-12 Santen Pharmaceutical Co., Ltd. Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof
CN103550144B (zh) * 2013-10-25 2015-10-14 深圳朗欧医药集团有限公司 盐酸左氧氟沙星组合物注射液及其制备方法
JP6363833B2 (ja) * 2013-11-22 2018-07-25 ナノシータ株式会社 薄膜状高分子構造体
CN104606198A (zh) * 2015-01-09 2015-05-13 周元铎 盐酸左氧氟沙星在制备防治家蚕细菌性败血病药中的应用
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3038722B2 (ja) 1989-06-23 2000-05-08 日本電気株式会社 接合型電界効果トランジスタ
JP3192290B2 (ja) 1993-08-04 2001-07-23 カネボウ株式会社 ポリエステル製耐熱ボトル
US7629458B2 (en) * 2001-10-03 2009-12-08 Teva Pharmaceutical Industries Ltd. Preparation of levofloxacin and hemihydrate thereof
US7169792B2 (en) * 2001-11-30 2007-01-30 Lg Life Sciences Ltd. Method of treating bacterial infections using gemifloxacin or a salt thereof and a β-lactam antibiotic
WO2005000307A1 (en) * 2003-06-26 2005-01-06 Santen Pharmaceutical Co., Ltd. Ophthalmic composition containing quinolones and method of use
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
JP2009526003A (ja) * 2006-02-10 2009-07-16 パーリ・ファルマ・ゲーエムベーハー 吸入療法用噴霧状抗生物質
WO2008005276A2 (en) * 2006-06-30 2008-01-10 Directcontact Llc Growth factor delivery system containing antimicrobial agents
EP2143422A1 (en) * 2008-07-11 2010-01-13 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections
CA2791190C (en) * 2010-02-25 2017-12-12 Santen Pharmaceutical Co., Ltd. Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof

Also Published As

Publication number Publication date
PH12012501674A1 (en) 2012-11-05
PH12016501747A1 (en) 2019-02-11
WO2011104981A1 (ja) 2011-09-01
US20120316158A1 (en) 2012-12-13
SG183427A1 (en) 2012-09-27
JP5600056B2 (ja) 2014-10-01
JP2013241464A (ja) 2013-12-05
EP2540299A4 (en) 2013-07-24
MX349603B (es) 2017-08-03
PH12016501747B1 (en) 2022-06-22
CA2791190C (en) 2017-12-12
JP5674882B2 (ja) 2015-02-25
JP2011195564A (ja) 2011-10-06
EP2540299A1 (en) 2013-01-02
BR112012021247A2 (pt) 2018-04-03
CN102770141A (zh) 2012-11-07
MY183483A (en) 2021-02-20
CA2791190A1 (en) 2011-09-01
AU2010346703A1 (en) 2012-09-20
JP2012162532A (ja) 2012-08-30
EP2540299B1 (en) 2016-04-13
NZ602126A (en) 2013-10-25
TW201129364A (en) 2011-09-01
HK1177887A1 (en) 2013-08-30
EA201290827A1 (ru) 2013-03-29
TWI488627B (zh) 2015-06-21
KR20170070265A (ko) 2017-06-21
ES2568647T3 (es) 2016-05-03
MX2012009844A (es) 2012-09-21

Similar Documents

Publication Publication Date Title
Kowalski et al. Intracameral Vigamox®(moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model
US20110294768A1 (en) Ophthalmic Suspension for Ocular Use
CN101766628B (zh) 一种眼科外用抗细菌感染药物
US20220287961A1 (en) Compositions and methods for treatment of ocular diseases
JP5674882B2 (ja) レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤
WO2016072440A1 (ja) 眼科用水性組成物
Tabbara et al. Treatment of acute bacterial conjunctivitis with topical lomefloxacin 0.3% compared to topical ofloxacin 0.3%
US20050009836A1 (en) Ophthalmic composition containing quinolones and method of use
JP2001010971A (ja) 眼感染症治療用眼軟膏剤
WO2016196989A1 (en) Topical composition
US20230338540A1 (en) Xanthan-based ophthalmic topical formulations with a reduced dosage regimen
Booysen South African Guide to topical ophthalmic drugs
HK1177887B (en) Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
Tabbara et al. Effects of fusidic acid on staphylococcal keratitis.
US11672798B2 (en) Ciprofloxacin ophthalmic topical composition for treating ocular disease
AKANDA et al. Efficacy of Perioperative Oral Antibiotics in the Prevention of Acute Infective Endophthalmitis after SICS
HK1178045A (en) Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
EP4611762A1 (en) Novel ophthalmic composition
Wada et al. Treatment of rabbit corneal infections with ophthalmic gatifloxacin: a concentration dependence study
Vaninbroukx et al. Preoperative eye disinfection in vitrectomy surgery using antibiotic or antiseptic eyedrops
WO2025229666A1 (en) Novel ophthalmic gel composition
CN114129590A (zh) 一种眼用组合物及其制备方法与应用
Sahoo et al. Management of Conjunctivitis in General Practice
Stevens et al. Fluoroquinolones for the treatment of microbial infections
Tiwari Pharmacological considerations in cataract surgery

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120914

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150629

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160530

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170313

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160530

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170612

PJ0201 Trial against decision of rejection

Patent event date: 20170612

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20170313

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20180430

Appeal identifier: 2017101002815

Request date: 20170612

J301 Trial decision

Free format text: TRIAL NUMBER: 2017101002815; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20170612

Effective date: 20180430

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20180430

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20170612

Decision date: 20180430

Appeal identifier: 2017101002815

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2018201005280; APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20180430

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190329

Appeal identifier: 2018201005280

Request date: 20180629

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2018201005280; JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20180629

Effective date: 20190329

PJ1302 Judgment (patent court)

Patent event date: 20190402

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20180629

Decision date: 20190329

Appeal identifier: 2018201005280

Appeal kind category: Appeal against decision to decline refusal